Indeed, selective inhibition of nNaVs, and of NaV1.6 in particular, whether using TTX analogs or a clinically relevant drug, riluzole, has been demonstrated to effectively suppress arrhythmias in murine models of CPVT (Radwański et al., 2015, 2016) and LQT3 (Radwański et al., 2013; Koleske et al., 2018). This evidence concerns the gene SCN5A and Arrhythmia.